All posts by imreal

MCG Interoperability Experts to Speak at HLTH 2022 Conference


MCG Health

MCG Health, part of the Hearst Health network

“This issue is critical to address, which is why we are looking forward to sharing how both payers and providers can reduce this administrative burden by using AI solutions.” – Rajesh Godavarthi, Associate VP of Technology and Interoperability, MCG Health

MCG Health, part of the Hearst Health network and an industry leader in technology-enabled, evidence-based guidance, announces four of its interoperability experts will present two sessions at HLTH 2022 happening November 13-16, 2022, in Las Vegas, Nevada. The HLTH event brings together leaders from across the healthcare ecosystem to encourage connections and thought-provoking discussions that push the boundaries of health innovation.

Daniel Cawood, MCG Product Manager of Interoperability Solutions, and Nick Engelhardt, MCG Senior Product Owner of Interoperability Solutions, will present the first technology talk, “Reducing Administrative Burden in Admission Authorizations,” on November 14, 2022, at 3:20 p.m. (PT). This session will discuss how MCG helped automate manual authorization submissions directly from the providers’ EHR between a payer and two hospitals for emergent inpatient admissions.

Natalie McGarry, MCG Senior Product Owner, and Rajesh Godavarthi, MCG Associate Vice President of Technology and Interoperability, will present the second tech talk, “Reducing Administrative Burden in Elective Procedure Authorizations,” on November 15, 2022, at 11:05 a.m. (PT). This presentation will cover how MCG helped automate manual authorization submissions for elective procedure admissions using the HL7 ® Da Vinci Project’s Implementation Guides’ (IGs) specifications.

“The healthcare industry has struggled with the authorization process for decades,” said Godavarthi. “CAQH’s Index from 2021 estimates that 35% of prior authorization requests in 2021 were submitted in a fully manual fashion (phone, fax, email, mail). This issue is critical to address, which is why we are looking forward to sharing how both payers and providers can reduce this administrative burden by using AI solutions.”

Daniel Cawood oversees the product development for MCG’s interoperability solutions and connecting payers and providers for authorization processes. Mr. Cawood began his time at MCG overseeing the Indicia suite of solutions (provider market clinical decision support) and value-based care solutions.

Nick Engelhardt is the Senior Product Owner for MCG’s interoperability solutions. Prior to joining MCG in March of 2022, he worked as a program manager for utilization management operations and care management operations at a large health system based in Cleveland, Ohio. Mr. Engelhardt’s experience in utilization and care management allows him to better understand the unique relationship between payers and providers. His work in interoperability solutions focuses on removing administrative burdens from clinical teams within payers and providers, creating a more efficient transaction that, ultimately, improves patient care.

Natalie McGarry has been with MCG for four years and is a Senior Product Owner for interoperability solutions. Her primary area of focus is building products that reduce administrative burdens. Before joining the interoperability team, Natalie was the Product Owner for MCG’s provider-facing solutions.

Rajesh Godavarthi has been with MCG Health since 2002. MCG is an Associate Member of the HL7® Da Vinci Project and Mr. Godavarthi leads the development efforts for that partnership. Prior to MCG, he was the Development Lead at Milliman and a lead developer at Intel. He received his Master’s in Computer Science from Osmania University.

For those interested in attending HLTH 2022, registration details and additional information can be found at: https://www.hlth.com/2022event.

###

About MCG Health

MCG, part of the Hearst Health network, provides unbiased clinical guidance that gives healthcare organizations confidence in delivering patient-centered care. MCG’s artificial intelligence and technology, infused with clinical expertise, enables its clients to prioritize and simplify their work. MCG’s world-class customer service ensures that clients maximize the benefits of licensing MCG solutions – demonstrating improved clinical and financial outcomes. For more information visit http://www.mcg.com or follow our Twitter handle at @MCG_Health.

About Hearst Health

The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Care guidance from Hearst Health reaches the majority of people in the U.S. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase and MHK (formerly MedHOK). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth and LinkedIn @Hearst-Health.

Share article on social media or email:



New Republic Partners Makes Strategic Investment in Innovation Fertility


Innovation Fertility, a network of leading IVF clinics and laboratories that provide IVF services and infertility care across the country, announced today an investment by New Republic Partners, an investment management and wealth advisory firm. The firm joined with Albaron Partners, the current owner of Innovation Fertility, to provide capital to support the long-term growth strategy of the healthcare platform.

The $8B U.S. fertility market includes in-vitro fertilization, genetic testing, reproductive tissue storage and donor services. This market continues to benefit from long-term demand drivers and strong growth rates.

Sam Bowles, managing director at New Republic Partners, says, “Albaron Partner’s deep experience in this industry coupled with strong market expansion opportunities makes this an attractive investment opportunity.”

Innovation Fertility is led by Dwight Ryan, chief executive officer, a seasoned healthcare executive with extensive years of financial, accounting and operations experience within the infertility industry, and Dr. Kathleen Miller, Chief Science Officer, a world-known leader for research advances in the field of blastocyst culture and pre-implantation genetics as well as a leading expert in laboratory management, quality improvement programs, and single embryo transfer.

Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine premier reproductive endocrinologists with laboratory operations, resulting in exceptional medical care and an unparalleled patient experience.

The organization’s growth strategies include plans to invest in practices across the U.S. to enable practice growth and profitability. Current investment holdings include practices in North Carolina, Ohio, Michigan and Montana.

About Us

Innovation Fertility

Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine premier reproductive endocrinologists with laboratory operations, resulting in exceptional medical care and an unparalleled patient experience. Learn more at http://www.iffertility.com.

New Republic Partners

New Republic Partners is an innovative investment management and wealth advisory firm serving successful individuals and families, endowments and foundations. Our clients benefit from access to investment opportunities usually reserved for large institutional investors, bespoke asset-class-specific fund offerings, customized portfolios, complex planning, and the expertise and experience of a successful and seasoned investment management, wealth advisory and credit solutions team. The firm is headquartered in Charlotte, North Carolina. More information is available at http://www.newrepublicpartners.com

Albaron Partners

Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with management teams and leverages its network of industry experts to augment its capabilities. For more information, visit http://www.albaronpartners.com.

Forward-Looking Statement

This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties. If any of these risks or uncertainties materialize, or assumptions by New Republic Partners, Albaron Partners or Innovation Fertility prove incorrect, results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to New Republic Partners, Albaron Partners and Innovation Fertility as of the date of this communication, and New Republic Partners, Albaron Partners and Innovation Fertility do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Share article on social media or email:

Top Trainer for Galderma and Allergan Opens New Aesthetic Injection Company in Scottsdale


Marissa Abdo, MS, RN, CANS

“Our service is unique in that we concentrate on a person’s anatomy when injecting in order to help clients attain the most beautiful results for their particular facial structure,” said Marissa Abdo, Aesthetic IQ Founder.

Marissa Abdo, MS, RN, CANS, a former team member of Beverly Hills’ Dr. 90210, has opened her own clinic in Scottsdale called Aesthetic IQ to help patients reach their full potential with specialized facial injectable treatments that include Botox, Dysport, Juvederm and Restylane dermal fillers, and Sculptra Aesthetic.

Abdo is a top national trainer for Allergan and Galderma with over a decade of industry experience. She specializes in natural, safe, and impactful injectable treatments and focuses on the anatomy of her clients’ facial structures to enhance their overall beauty. Abdo established Aesthetic IQ, a brand-new, exclusive medical aesthetic clinic, using her expertise as a national educator to provide clients looking to improve their looks with a completely unique experience.

“Your injectable procedures should not only enable you to present your finest face, but also give you the confidence and self-assurance to do so,” said Marissa Abdo, Aesthetic IQ Founder. “Our service is unique in that we concentrate on a person’s anatomy when injecting in order to help clients attain the most beautiful results for their particular facial structure.”

The term “Aesthetic Intelligence,” from which “Aesthetic IQ” is derived, refers to using the power of the senses to produce treatments, results, and an elevated aesthetic experience while bridging the gap between the art and science of injectables. The goal of Aesthetic IQ is to provide patients with meaningful and impactful treatments as well as an immersive experience that makes them feel informed, appreciated, and confident that they are receiving the safest and most effective injectable care possible.

At the clinic, patients will be able to receive chin filler, lip augmentation, tear trough filler, non-surgical brow lift, non-surgical neck lift, cheek and jaw augmentation, and other injectable treatments.The Aesthetic IQ clinic is open Monday through Friday from 9 am-5 pm. For more information, call 480.454.5577, visit AestheticIQClinic.com or visit their location at 7054 E Cochise Rd. B200 Scottsdale, AZ 85253. You can follow the clinic on social media at – @Marissa.AestheticIQ.

About Marissa Abdo

Aesthetic IQ’s founder, Marissa Abdo, MS, RN, CANS, was formerly on the staff of Beverly Hills’ Dr. 90210 and is a preferred injector for Hollywood’s elite and celebrities. At this unique aesthetic clinic, Abdo focuses on her clients’ facial anatomy to improve their overall beauty. She is a firm believer in empowering women both through her professional services and through education. As a top national trainer for Galderma and Allergen, Abdo has trained healthcare professionals at more than 100 locations in the Scottsdale area. She is dedicated to creating an empowered community of practitioners who can safely administer injections to all patients and believes that every injector should have a seat at the table. In terms of service and outcomes, Abdo is leading the way and establishing the bar for the injection industry. Through Aesthetic IQ, she is pleased to provide each patient—from mature patients and even men—with a personalized experience. Each patient receives assistance from Abdo in realizing their beauty and their unique contribution to the world.

Share article on social media or email:

Dr. Ashley Shayter Selected Act Early Ambassador of Michigan


AAoM

AutismAlliance of Michigan

“I’m very excited to be the CDC’s Act Early Ambassador for Michigan! Empowering parents with tools to watch their child grow and thrive is so important, says Dr. Ashley Shayter. We know that early intervention is key to maximizing long-term benefits…..”

Southfield, Michigan (November 3, 2022) — The Autism Alliance of Michigan (AAoM) is pleased to announce that Dr. Ashley Shayter, PhD, LBA, BCBA-D, CBIS, Policy Manager for Statewide Education & Outreach, has been selected as CDC’s Act Early Ambassador to Michigan.

Act Early Ambassadors work with CDC’s Learn the Signs. Act Early. program to improve early identification of developmental delays and disabilities so that children and their families can access needed services as early as possible.

“This is such a significant opportunity for AAoM and our state, said Colleen Allen, Ph.D., President and CEO of AAoM. Reducing the age of diagnosis and access to critical services is one of our major strategic initiatives over the next 10 years. The Learn the Signs. Act Early. Campaign is perfectly aligned with this work. Dr. Shayter’s role as Ambassador will allow us to connect with national experts, colleagues in other states addressing this priority, and resources to share with stakeholders”.

Since 2011, professionals with medical, child development, developmental disability, special education, and early intervention expertise have been selected to serve as a state or territorial point-of-contact for the national Learn the Signs. Act Early. program. The ambassador supports the work of Act Early Teams and other Michigan-specific initiatives to improve early identification of developmental delay and disability; and promote the adoption and integration of Learn the Signs. Act Early. resources into systems that serve young children and their families.

“I’m very excited to be the CDC’s Act Early Ambassador for Michigan! Empowering parents with tools to watch their child grow and thrive is so important, says Dr. Ashley Shayter. We know that early intervention is key to maximizing long-term benefits. I hope my work as the Act Early Ambassador will encourage everyone who interacts with young children–from families to healthcare organizations to educators–to use the Learn the Signs. Act Early. materials and resources so we can ensure a bright and successful future for Michigan’s children.”

Click here to read more about CDC’s Act Early Ambassadors.

About Autism Alliance of Michigan

Since 2009, The Autism Alliance of Michigan (AAoM) has led collaborative efforts across the state that improve the quality of life for individuals with autism through education, comprehensive services, community awareness, inclusion efforts and coordinated advocacy across their lifespan. AAoM is the trusted ally and partner for thousands of families.  An AAoM navigator can be reached at 877-463-2266 (AAOM) or email at navigator@aaomi.org. For information on events, resources and donations, or for more information on the Watch Me Grow program, please visit autismallianceofmichigan.org.

# # #

Share article on social media or email:

Leitner Varughese Warywoda Argues Bellweather Case before the US Court of Appeals, Second Circuit to Determine Fate of Thousands of Nursing Home Death Lawsuits


We eagerly await the Court’s Decision so that discovery may commence in these tragic circumstances”, stated Brett R. Leitner, counsel for Rivera-Zayas.

Leitner Varughese Warywoda represents Vivian Rivera-Zayas, the daughter and administrator of the estate of Ana Martinez, who was admitted to Our Lady of Consolation Nursing & Rehabilitation Care Center in West Islip, New York for a short-term stay for physical therapy with the plan to return home after a few weeks. It is alleged that she never left the facility and reportedly died of COVID because of Our Lady of Consolation’s failure to implement proper infection control measures in violation of federal and state rules, specifically the “abject and longstanding failure to maintain a system for preventing, identifying, reporting, investigating and controlling infections and communicable diseases,” according to the complaint, which is attached. The case is Rivera-Zayas v. Our Lady of Consolation Geriatric Care Center et al., case number 2:20-cv-05153, in the U.S. District Court for the Eastern District of New York.

Our Lady of Consolation, along with two lobbying groups for New York hospitals and nursing home owners, the Greater New York Hospital Association and the Healthcare Association of New York State, previously filed briefs in the Eastern District of New York seeking to dismiss the suit, claiming the Public Readiness and Emergency Preparedness Act (PREP Act) bars lawsuits against nursing homes during a public health emergency. The Hon. Nicholas G. Garaufis, United States District Judge, sided with Leitner Varughese Warywoda, and denied the nursing home’s motion to dismiss the lawsuit, allowing it to proceed in New York State Supreme Court (decision attached).

Defendant Our Lady of Consolation appealed to the United States Court of Appeals for the Second Circuit, assisted by a congregation of powerful New York State and national lobbying groups also submitting briefs in favor of the nursing home, including Greater New York Hospital Association (“GNYHA”), the Healthcare Association of New York State, Inc. (“HANYS”), Atlantic Legal Foundation, DRI (Defense Research Institute), The Chamber of Commerce of The United States of America, the American Medical Association, and the Medical Society of the State of New York. The Court of Appeals docket is attached.

”The simple truth here is that Ms. Rivera-Zayas does not allege that her mother died because of “the administration or use of a covered countermeasure” by anyone, but rather because of Our Lady of Consolation’s broad failures to adopt effective infection-control policies—policies that are not “covered countermeasures. We eagerly await the Court’s Decision so that discovery may commence in these tragic circumstances”, stated Brett R. Leitner, counsel for Rivera-Zayas.

Rivera-Zayas is represented by Brett R. Leitner, Justin Varughese, and Nicholas E. Warywoda of Leitner Varughese Warywoda PLLC, with Adam Pulver, an attorney with Public Citizen, a nonprofit consumer advocacy organization based in Washington D.C., on the appeal.

An audio transcript of the argument can be found here: https://rb.gy/gtznbw.

About Leitner Varughese Warywoda

Leitner Varughese Warywoda is a cutting-edge litigation and trial law firm uniquely experienced in handling high-profile, complex lawsuits involving serious injuries and wrongful death. The Firm has specific interest in handling cases of neglect and abuse involving nursing home residents and medical practices. The firm has recovered over $200 million on behalf of clients that were injured as a result of car and truck accidents, construction accidents (involving New York State Labor Law violations), slip/trip and falls, and nursing and medical negligence. The attorneys’ jury verdicts and settlements have been recognized among the top largest personal injury jury verdicts in New York State and in the United States, and have been featured in the Top New York Verdicts and Verdicts and Settlements Hall of Fame publications.

Learn more about Leitner Varughese Warywoda here https://www.lvlawny.com.

Share article on social media or email:

Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse


We saw a 10% improvement in event-free survival — a real breakthrough. That’s quite a big gain, especially in pediatric Hodgkin lymphoma.

— A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children’s Oncology Group(COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children’s Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse. The findings were published today in the New England Journal of Medicine (NEJM). *

“We saw a 10% improvement in event-free survival — a real breakthrough,” says study senior author Kara Kelly, MD, Chair of the Roswell Park Oishei Children’s Cancer and Blood Disorders Program, and also Division Chief of Hematology/Oncology in the Department of Pediatrics at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo. “That’s quite a big gain, especially in this field. We expect that this treatment regimen will soon become standard of care for pediatric patients with high-risk Hodgkin lymphoma.”

The clinical trial, AHOD1331 (NCT02166463), was funded by the National Cancer Institute (NCI) of the National Institutes of Health and conducted at 153 COG sites. The study was also supported by Seagen, formerly known as Seattle Genetics, and the St. Baldrick’s Foundation. The study was sponsored by the Division of Cancer Treatment and Diagnosis, NCI, and the brentuximab vedotin was provided by Seagen under a Cooperative Research and Development Agreement with NCI.

“This trial reflects a paradigm shift for advanced-stage Hodgkin lymphoma in children, and an introduction of the first targeted approach for initial therapy in pediatric Hodgkin lymphoma and the first new regimen in two decades,” says study first author Sharon Castellino, MD, MSc, Director of the Leukemia and Lymphoma Program at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, Professor of Pediatrics at Emory University School of Medicine, and a research member at Winship Cancer Institute of Emory University. Dr. Castellino succeeded Dr. Kelly this year as COG Hodgkin Committee Chair. “We are optimistic that this trial will set the stage for FDA approval of this targeted antibody-drug conjugate for children and adolescents.”

Study Vice Chair and Co-Author Frank Keller, MD, Pediatric Hematologist/Oncologist at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Professor of Pediatrics at Emory University School of Medicine, adds: “The demonstration of the effectiveness of a highly targeted treatment directed against the malignant cell population in newly diagnosed pediatric and young adult patients with high-risk Hodgkin lymphoma is a significant step forward toward improving cure rates and may do so without adding significant long-term toxicity for this young population with many years of life remaining.”

HL is the most common cancer in patients 12-29 years old. Although it has a high five-year survival rate — 97% of those under 19 are alive five years after diagnosis — about one-third of survivors are classified as high risk; of those, approximately 15-20% will relapse.

The COG study — the largest and only randomized phase 3 trial with the CD-30-targeted ADC ever conducted with newly diagnosed high-risk HL pediatric patients — involved 587 patients ages 2-21 with previously untreated disease.

Patients were randomized to one of two arms, both arms receiving treatment over five 21-day cycles. Those in the control group received the standard pediatric chemotherapy regimen.

The second group received the standard pediatric chemotherapy regimen, plus brentuximab vedotin. Brentuximab vedotin (BV) is an antibody-drug conjugate that specifically targets the CD30 protein on the surface of HL cancer cells, destroying them while mostly sparing healthy cells.

Both groups received site radiation therapy based on responses assessed after two cycles of treatment.

Follow-up at about three and a half years after treatment showed 92.1% event-free survival in the brentuximab vedotin group, compared with 82.5% for the control group — an overall risk reduction of 59% of relapse, death or a second malignant neoplasm.

Lower risk of relapse could possibly eliminate the need for re-treatment with additional toxic therapies. Over the long term, treatment toxicity puts HL survivors at very high risk of breast cancer, stroke, myocardial infarction, restrictive pulmonary disease, infertility and shortened lifespan.

“Brentuximab vedotin is not anticipated to have long-term toxicity,” says Dr. Kelly, noting that during the treatment phase of the clinical trial, less than 10% of patients who received it needed a dose reduction. “Because the drug could be given more consistently, its efficacy improved with no increase in neuropathy or serious infection.”

Dr. Kelly, Dr. Castellino and colleagues will build on these findings in a new clinical trial set to open in early 2023 with support from the National Cancer Institute. The phase 3 randomized study will enroll approximately 1,900 children and adults ages 5-60 with medium- and low-risk HL. The goal: to determine whether the combination of the the CD30 targeted ADC brentuximab vedotin and immunotherapy agent nivolumab can prolong progression-free survival and further reduce patients’ exposure to standard chemotherapy and radiation. Patients will be followed for 12 years to monitor their progress and gauge the results.

Allison Brashear, MD, Vice President for Health Sciences at the University at Buffalo and Dean of the Jacobs School of Medicine and Biomedical Sciences, says results of the study “mean a greatly improved quality of life for the most vulnerable and courageous patients — children with cancer.

“As one of the largest demonstrations of a successful immuno-oncologic approach in children with cancer,” Dr. Brashear notes, “it is a powerful example of what happens when extraordinary institutions decide that collaboration is key to their success.”

Lucky Jain, MD, MBA, Pediatrician-in-Chief for Children’s Healthcare of Atlanta, and Chair of the Department of Pediatrics for Emory University School of Medicine, says, “A 10 percent reduction in relapse among children with high-risk Hodgkin lymphoma is a significant milestone for the field of pediatric cancer. Children’s Healthcare of Atlanta and Emory University are proud of this incredible leap forward led by our physicians, Dr. Sharon Castellino and Dr. Frank Keller, along with their collaborators and the Children’s Oncology Group.”

*Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number NCTN Operations Center Grant U10CA180886 and NCTN Statistics & Data Center Grant U10CA180899. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

About Roswell Park

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

About Children’s Healthcare of Atlanta

As the only freestanding pediatric healthcare system in Georgia, Children’s Healthcare of Atlanta is the trusted leader in caring for kids. The not-for-profit organization’s mission is to make kids better today and healthier tomorrow through more than 60 pediatric specialties and programs, top healthcare professionals, and leading research and technology. Children’s is one of the largest pediatric clinical care providers in the country, managing more than one million patient visits annually at three hospitals, Marcus Autism Center, the Center for Advanced Pediatrics, urgent care centers and neighborhood locations. Consistently ranked among the top children’s hospitals by U.S. News & World Report, Children’s Healthcare of Atlanta has impacted the lives of kids in Georgia, across the United States and around the world for more than 100 years thanks to generous support from the community.

About Winship Cancer Institute of Emory University

As the only National Cancer Institute-designated Comprehensive Cancer Center for the state of Georgia, Winship Cancer Institute of Emory University discovers, develops, delivers and teaches some of the world’s most effective ways to prevent, detect, diagnose and treat each patient’s unique cancer. For more information, visit winshipcancer.emory.edu.

About the Jacobs School of Medicine and Biomedical Sciences at UB

The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo is proud of its legacy advancing the best in medical education, clinical care and scientific discovery. Today, the Jacobs School is at the center of Buffalo’s comprehensive academic health center. With UB’s other four health sciences schools and its School of Social Work, the Jacobs School prepares tomorrow’s health leaders at both the lab bench and the bedside to benefit the health and wellness of the people of Western New York, New York State and the world. Founded in 1846, the school provides care for the region’s diverse population through strong clinical partnerships and its practice plan, UBMD Physicians’ Group. UB is a premier, research-intensive public university, and it is a flagship institution of the State University of New York. UB is a member of the Association of American Universities, which is composed of America’s leading research universities.

About The Children’s Oncology Group (COG)

COG (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world’s largest organization devoted exclusively to childhood and adolescent cancer research. COG unites over 10,000 experts in childhood cancer at more than 200 leading children’s hospitals, universities, and cancer centers across North America, Australia, and New Zealand in the fight against childhood cancer. Today, more than 90% of the 16,000 children and adolescents diagnosed with cancer each year in the United States are cared for at COG member institutions. Research performed by COG institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 80%. COG’s mission is to improve the cure rate and outcomes for all children with cancer.

CNI College Students Elected to California Nursing Students’ Association Board of Directors


CNI College Bachelor of Science in Nursing (BSN) students Clarisse Paul and Jonathan Calderon have been elected to serve on the Board of Directors for the California Nursing Students’ Association (CNSA). Ms. Paul will serve as the Vice President and Mr. Calderon will serve as a General Board Member. CNSA is a constituent chapter of the National Student Nursing Association (NSNA) and has over 5,000 members state-wide. The members are committed in seeking optimal educational, developmental, and professional growth within today’s various healthcare settings.

“As someone who one day wants to be involved in nursing education, I wanted to be on the board to work alongside people from other programs with similar goals and aspirations. I am looking forward to advocating for our classmates and promoting a good learning experience for students around the state,” said Jonathan Calderon.

“I took this position to become an advocate for change and to represent our student body,” said Clarisse Paul on her election.

“We are incredibly proud of Jonathan and Clarisse in their election to the CNSA Board,” said CNI College founder Colleen Buffington. “Their dedication to the field of nursing is encouraging to their classmates, faculty, and staff at CNI College. We are inspired by their leadership and commitment to serve their fellow nursing students and healthcare community throughout California.”

About CNI College

CNI College, based in Orange County, is a provider of career education. CNI College is institutionally accredited by the Accrediting Bureau of Health Education Schools (ABHES). The baccalaureate degree program in nursing is accredited by the Commission on Collegiate Nursing Education (CCNE). CNI College offers six (6) distinct career programs; Bachelor of Science in Nursing (BSN), RN to BSN, Vocational Nursing (VN), AOS Surgical Technology, AOS MRI Technology, and Medical Assisting. Each of these programs are designed to prepare students with the knowledge, skills, competencies, and professional education necessary to achieve their desired diploma and or license and assist the graduates in becoming gainfully employed in their chosen field. The CNI College Student Services Department provides the necessary resources like skills coaching, job fairs, mentoring, and career guidance to help students fulfill their dreams. To find out more about CNI College programs, contact CNI College at (888) 985-5908 or visit the website at http://www.cnicollege.edu.

Share article on social media or email:

The DRIPBaR is excited to announce the latest opening in Suwanee, GA as of October 29, 2022


The DRIPBaR is excited to announce the latest opening in Suwanee, GA as of October 29, 2022.

The DRIPBaR is excited to announce the latest opening in Suwanee, Georgia as of October 29, 2022. The franchise has approximately 500+ additional locations in the pipeline.

Owned and operated by longtime locals Anky Desai and Arpit Patel, The DRIPBaR Suwanee is the newest location for the growing DRIPBaR franchise. After seeing the healing benefits of IV therapy firsthand, and fueled by their years of experience as Licensed Pharmacists, the pair is excited to bring the cutting-edge therapies of the franchise to their community.

Customers will have a variety of IV Lifestyle Drips & IV Health Support Drips to choose from, including the popular Powerpack and Allstar drips. This location also offers Functional Diagnostics and Laboratory Testing, which can help identify the root cause of disease by providing a closer look at the body as a whole. These services are designed to help customers look and feel their very best – whether they are looking for a quick boost or a more long-term wellness solution.

For those who don’t have time for a full vitamin infusion but want the benefit, clients can choose one of five IM Quick Shots that give the body a boost in just five minutes.

Designed to offer quick doses of powerful and optimally-balanced nutrients and formulas, The DRIPBaR’s infusions are well known for boosting energy, hydrating, detoxing from chemicals and toxins, improving overall health and vitality, and addressing more specific wellness needs.

To celebrate their arrival, The DRIPBaR Suwanee will offer 50% off any drip service plus a FREE B12 quick shot on your first visit. Appointments can be booked here!

About The DRIPBaR

Founded in 2016, The DRIPBaR is a nationwide-based franchise focused on helping people obtain their best physical and mental health using intravenous therapies.

Through advances in cellular and biological science, The DRIPBaR helps clients fight the consequences of chronic illness, address the effects of aging, and achieve balanced wellness. With a focus on ever-evolving treatments and medical advancements, the franchise hopes to shorten the gap between concierge and treatment-based medicine.

With 30+ locations currently open and operating, The DRIPBaR already has more than 500 additional locations in various stages of development across 28 states. For more information, visit http://www.thedripbar.com.

The DRIPBaR Suwanee

4369 Suwanee Dam Rd #102B

Suwanee, GA 30024

(470) 780-4401

suwanee175@thedripbar.com

Share article on social media or email:

Men Having Babies’ Board Endorses SEEDS Standards of Ethical Conduct for Surrogacy Agencies


Men Having Babies Board Endorses SEEDS Standards of Ethical Conduct for Agencies

Men Having Babies Board Endorses SEEDS Standards of Ethical Conduct for Agencies

“We feel that the creation of the SEEDS Standards will serve to codify and even improve upon prevailing best practices that already set the US and Canada apart among other countries where surrogacy is practiced.”

Men Having Babies (MHB) is pleased to announce its board’s formal endorsement of The Society for Ethics for Egg Donation and Surrogacy’s (SEEDS) new Standards of Ethical Conduct for Member Agencies. These new standards constitute the first time that professionals involved in gestational surrogacy and egg donation in the United States have created self-binding standards, as compared to the longstanding ethical frameworks that apply to medical, legal, and mental health providers involved in surrogacy and egg donation. “We feel that the creation of the SEEDS Standards will serve to codify and even improve upon prevailing best practices that already set the US and Canada apart among other countries where surrogacy is practiced,” said Ron Poole-Dayan, MHB’s founder and executive director. “Some differences still exist between the positions of SEEDS and those of MHB, and the terminology we use is sometimes different. However, the new SEEDS Standards reflect many of the values we share, and they are a testament to the professionalism of those working in this field.”

In addition to the board’s endorsement of these Standards, Men Having Babies is proud to announce that beginning in 2024 all US based surrogacy agencies that participate in MHB events and the Gay Parenting Assistance Program will be asked to demonstrate adherence to these new SEEDS Standards. MHB hopes that this will be another step in the direction of making these Standards widespread and promoting the United States as a place dedicated to the ethical operation of agencies that provide gestational surrogacy and egg donation services.

Men Having Babies is proud to have played a unique, supporting role in the development of these groundbreaking standards. Lisa Schuster, MHB’s director of programming and a former gestational surrogate, has been invited as an observer to SEEDS’s Standards Committee, and provided input and observation through the lens of MHB’s mission of promoting ethical surrogacy practices that minimize the risks and maximize the potential short and long-term benefits to all involved.

Not only do the Standards address professional aspects related to the business and operational conduct of member agencies, Men Having Babies is especially proud to highlight details of the Standards that, in line with MHB’s Framework for Ethical Surrogacy for Intended Parents, address issues related to the rights and wellbe- ing of all parties involved.

Men Having Babies applauds SEEDS’ use of the LGBTQ+ inclusive definition of infertility to be used in screening intended parents for surrogacy. This language comes from the inclusive definition of infertility, which MHB helped to draft, used by RESOLVE: The National Infertility Association in their model legislation, and which has already been passed in new legislation in Illinois last year. The Standards embrace the concept of ‘status’ as it relates to infertility, in addition to the medical condition and disease, prohibiting agencies from providing services to those who do not “demonstrate a need for surrogacy associated with a disease, condition, or status characterized by […] a person’s inability to reproduce either as a single individual or with their partner without medical intervention”. This position corresponds to MHB’s Ethical Framework which advocates that surrogacy should be legally allowed as a parenting option to individuals, single or coupled, that lack the reproductive capacity to become parents without the help of a surrogate or have a medical reason for needing the help of a surrogate, but not to women who simply do not desire to become pregnant – sometimes referred to as “social surrogacy”.

Also, in the spirit of MHB’s Ethical Framework are SEEDS’s efforts to curb the over-commercialization of the field by detailing acceptable practices relating to advertising, and prohibition of the use of inaccurate, misleading, or coercive information, or placing undue emphasis on monetary incentives and compensation to potential donors or surrogates. With respect to compensation, Men Having Babies is pleased that, given the unique and unexpected circumstances that can arise in any surrogacy journey, the Standards prohibit the bundling of the recompense for the personal sacrifice and risks associated with the surrogacy process into a “flat rate” along with reimbursements for out-of-pocket expenses and compensation associated with specific contingencies.

Men Having Babies applauds the hard work and dedication of the professionals involved in surrogacy and egg donation and, in line with our policies related to ethical surrogacy, is proud to endorse these new Standards.

About Men Having Babies

The international nonprofit Men Having Babies (MHB) is dedicated to providing current and future gay fathers with unbiased advice, support, and financial assistance. The organization’s Membership Benefits Program (MBP) offers a wide range of exclusive guidance resources, including MHB’s unique Peer Advice Parent Network, and access to discounts from over 160 surrogacy providers. Among the benefits of membership is the ability to apply to the Gay Parenting Assistance Program (GPAP), which annually provides hundreds of individuals or couples with over a million dollars worth of cash grants, discounts, and free services from leading service providers. MHB’s annual conferences offer unbiased guidance and access to a wide range of relevant service providers. Their extensive online resources include FAQs, a video library, Ask the Expert articles, and a comprehensive surrogacy and gay parenting research library. The organization also offers a comprehensive Surrogacy Providers Directory, including ratings and reviews of agencies, clinics and law firms. MHB’s Advisory Board of distinguished surrogacy professionals leads the provision of expert advice to members, and our framework for Ethical Surrogacy has received endorsements from LGBT parenting organizations worldwide.

For more information about Men Having Babies, visit menhavingbabies.org

About The Society for Ethics for Egg Donation and Surrogacy’s (SEEDS)

SEEDS is a nonprofit organization founded by a group of egg donation and surrogacy agencies, whose purpose is to define and promote ethical behavior by all parties involved in third party reproduction. SEEDS, which stands for the Society for Ethics in Egg Donation and Surrogacy, carries out its mission by working with ART professionals to create a unified voice and develop and issue ethical standards for the various aspects of third party reproduction. We have currently developed several standards, and many more are planned. Our goal is to reach a wide audience of agencies and ART professionals and hear their opinions and input about industry standards. Ideally we will come to industry-wide agreement on the standards.

For more information about SEEDS: https://seedsethics.org/

Share article on social media or email:

Applications Now Open for 2023 National STEM Scholar Class


Middle School Science Teachers Participate in National STEM Scholar Program

The National STEM Scholar Program selects 10 teachers each year from a national pool of applicants based solely on their description of a “big idea” Challenge Project they would implement in their classrooms if funds were available.

Applications are now open for middle school science teachers nationwide to apply for a spot in the 2023 class of the National STEM Scholar Program, a unique professional development program providing advanced STEM (science, technology, engineering and math) training, national network building, and “big idea” project support for the middle school teachers of aspiring scientists.

Created in partnership between the National Stem Cell Foundation and The Gatton Academy of Mathematics and Science at Western Kentucky University (WKU), the National STEM Scholar Program selects 10 teachers each year from a national pool of applicants based solely on their description of a “big idea” Challenge Project they would implement in their classrooms if funds were available. In addition to weeklong training and project development on the campus of WKU, each class spends a day with a nationally or internationally recognized STEM speaker. Past speakers have included Dr. Eric Mazur, Balkanski Professor of Physics and Applied Physics at Harvard University, Dr. John Medina, author of New York Times bestseller Brain Rules, and Michelle Lucas, CEO of Higher Orbits, inspiring student passion for STEM through spaceflight.

There are currently 70 STEM Scholars representing middle schools in 31 states, from Alaska to New York and Wisconsin to Florida. Each successful Scholar applicant receives the following:

  • Advanced STEM education and leadership training on the campus of WKU May 28 – June 3, 2023. All expenses – travel, lodging, meals – are included
  • A notebook/tablet (Chromebook or similar) to facilitate ongoing collaboration
  • A generous stipend for technology and supplies to implement a classroom Challenge Project
  • Sponsored attendance at the National Science Teaching Association (NSTA) National Conference in March/April 2024. All expenses – registration, travel, lodging, meals – are included
  • Year-long mentorship and support provided by WKU faculty

Applications are open now. Please apply at http://www.wku.edu/gifted/nss.

About the National Stem Cell Foundation:

The National Stem Cell Foundation (NSCF) funds adult stem cell and regenerative medicine research, underwrites the National STEM Scholar Program for middle school science teachers nationwide, and covers copays and deductibles for children of limited means participating in clinical trials for rare diseases. We build collaborations, form partnerships, and leverage our relationships in research, education, and advocacy to solve problems and magnify impact. For more information, visit http://www.nationalstemcellfoundation.org.

About The Gatton Academy:

Established in 2007, The Gatton Academy is Kentucky’s first residential two-year program for gifted and talented juniors and seniors. The Gatton Academy’s students enroll as juniors and are full-time WKU students pursuing their interests in advanced science, technology, engineering, and mathematics. The Gatton Academy has been named to Jay Mathews’ list of top-performing schools with elite students for eleven consecutive appearances and received the National Consortium for Secondary STEM School’s Innovation Partnership Award. For more information, visit http://www.wku.edu/academy/.

Share article on social media or email: